Verastem (VSTM) Stock May Be Undervalued Despite VS7375 Progress
Verastem Stock In Focus After Earnings Update And New Financing Plans
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
Verastem (NASDAQ:VSTM) Passes Minervini Trend Template but Setup Rating Signals Patience
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
What Verastem (VSTM) Said on Its Q3 Earnings Call
Verastem (VSTM) Q3 2026 Earnings Call Transcript
Verastem (VSTM) Wins FDA Priority Review, Is The Stock Cheap Or Priced For More?
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $18
Verastem, Inc. (VSTM) Q3 2026 Earnings Call Transcript
Verastem, Inc. Q3 2026 Earnings Call Summary
Verastem Inc (VSTM) Q3 2026 Earnings Call Highlights: Avmapki Revenue Surges 114% as VS-7375 ...
HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $20
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates
Verastem: Q3 Earnings Snapshot
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology Q3 2026 Earnings Call Transcript
Verastem Oncology Files $100M At-The-Market Equity Offering Agreement With Cantor Fitzgerald
Verastem Q3 Adj. EPS $(0.72) Misses $(0.46) Estimate, Sales $24.012M Miss $26.078M Estimate
Verastem Oncology to Participate in Upcoming November Investor Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.